Vanta Bioscience Board of Directors

Get the latest insights into the leadership at Vanta Bioscience. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Dopesh Raja Mulakala Managing Director
Dr. Yogeswara Rao Danda Ind. Non-Executive Director
Dr. Gonuguntla Kathyayani Ind. Non-Executive Director
Dr. Padmanabhuni Venkata Appaji Ind. Non-Executive Director

Vanta Bioscience Share price

VANTABIO

21

0.00 (0.00%)
Last updated on 9 Jan, 2026 | 13:02 IST
alert_iconwatchlist_icon
BUYSELL
Today's High

21.00

Today's Low

21.00

52 Week Low

16.85

52 Week High

42.85

alert_iconThe current prices are delayed, login to your account for live prices

Vanta Bioscience FAQs

The board at Vanta Bioscience consists of experienced professionals, including Mr. Dopesh Raja Mulakala , Dr. Yogeswara Rao Danda , and others, overseeing the company’s strategic and corporate governance.

Directors at Vanta Bioscience are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Dopesh Raja Mulakala is the current chairman at Vanta Bioscience.

Executive directors at Vanta Bioscience are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Vanta Bioscience adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Vanta Bioscience, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.